menu search

Ibio further expands tech stack with shieldtx™; enhances immuno-oncology development pipeline with conditionally activated muc16xcd3 bispecific

shieldtx potentially increases safety and developability of therapeutic antibodies for difficult ta...

November 1, 2023, 12:24 pm


Search within

Pages Search Results: